CDR-Life
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Wagistrasse 27, Schlieren, Zurich, 8952,...Phone Number
+41 445159898Website
www.cdr-life.comRevenue
$9.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About CDR-Life
CDR-Life, a biotherapeutics company, develops novel immunotherapies that target the power of the immune system specifically to tumor cells. Based on a proprietary antibody platform that targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, the company is advancing a portfolio of tumor-specific T cell engagers for the treatment of high need solid tumor malignancies. CDR-Life is led by former biologics inventors, pharmaceutical drug developers and company builders, and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration.Explore more
CDR-Life Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CDR-Life your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on CDR-Life recently announced quarterly report
Check out if CDR-Life is spiking on competitors!
Check if CDR-Life has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when CDR-Life launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at CDR-Life
Click to see if CDR-Life had a recent Job posting/layoffs
Funding: Get notified immidiatlly once CDR-Life has new funding data
CDR-Life, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at CDR-Life
Find more new buyers
Company Profile Activity
Activity Insights
CDR-Life is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CDR-Life is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CDR-Life.
CDR-Life financials insights
Gather financial insights about CDR-Life, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$76M
CDR-Life Tech Stack
A closer look at the technologies used by CDR-Life
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
CDR-Life News & Media
CDR-Life Announces CDR609 as New T-Cell Engager Clinical Candidate Targeting LGR5, a Highly Cancer-specific Surface Antigen Widely Expressed on Common Solid Tumor
ZURICH--(BUSINESS WIRE)--CDR-Life Inc., a biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced CDR609 as its next clinical candidate. CDR609 is a novel TCE targeting LGR5, a surface antigen that presents a compelling opportunity for broad, tumor-specific therapeutic intervention in solid tumors. LGR5 is a challenging and largely underexploited target in cancer immunotherapy. Unlike most other highly cancer-specific tarCDR-Life Appoints Pascal Touchon to the Board of Directors to Support Continued Growth and Advancement of Next Generation T Cell Engager Platform
ZÜRICH--(BUSINESS WIRE)--CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with extensive expertise in oncology and strategic leadership that will further strengthen CDR-Life as it advances its innovative M-gager® platform and pipeline of T cell engager (TCE) therapeutics. “We are delighted to welcome Pascal to our Board of Directors,” said Dominik Escher, PhCDR-Life Presents Promising Preclinical Data for Novel T Cell Engager Programs at AACR Annual Meeting 2025
ZURICH--(BUSINESS WIRE)--CDR-Life today announced the presentation of data for its novel T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations showcase the company's proprietary M-gager® platform-derived TCE candidates, with a focus on CDR404, currently in Phase 1 clinical trials for MAGE-A4-positive solid tumors. “The data presented at AACR highlight the potential advantages of our antibody-based approach to T celCDR-Life Demonstrates Commitment to Differentiated Pipeline with New Autoimmune Candidate CDR111
ZÜRICH--(BUSINESS WIRE)--CDR-Life today announced the expansion of its product portfolio with the nomination of CDR111 as a new clinical candidate for autoimmune diseases along with upcoming posters highlighting the company's T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, Illinois. Portfolio Expansion: CDR111 CDR111, CDR-Life’s newest clinical candidate, is a trispecific molecule targeting CD19, BCMA and
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding CDR-Life
Sign Up For FreeTo access detailed company insights
CDR-Life, a biotherapeutics company, develops novel immunotherapies that target the power of the immune system specifically to tumor cells. Based on a proprietary antibody platform that targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, the company is advancing a portfoli... Read More
